Given the growing interest in targeting de novo pyrimidine synthesis as a PDAC dependency, we propose a combination strategy of DHODH and BCL-XL inhibition that can induce anti-tumor responses with potential clinical translatability. The gene discussed is BCL2L1; the disease is neoplasm.